AMENDMENT UNDER 37 C.F.R. § 1.116

Application No.: 10/534,066

Attorney Docket No.: Q87744

**AMENDMENTS TO THE CLAIMS** 

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (Currently amended) A method for preparing a microemulsion concentrate for

oral administration of a water-insoluble anti-cold drug comprising (a) dissolving the water-

insoluble anti-cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding a

surfactant and an oil in the drug solution to obtain a microemulsion pre-concentrate; and (c)

removing the co-surfactant from the pre-concentrate, wherein the microemulsion concentrate

forms microparticles having an average particle size ranging from 270 to 500 nm upon contact

with an aqueous solution.

2. (Original) The method of claim 1, wherein the water-insoluble anti-cold drug is

selected from the group consisting of acetaminophen, ibuprofen, S-ibuprofen, dextromethorphan

hydrobromide, noscapine hydrochloride, trimetoquinol hydrochloride, guaifenesin, d-

chlorpheniramine maleate, carbetapentane citrate, tipepidine citrate, cloperastine hydrochloride,

cloperastine fendizoate, tipepidine hibenzate, d, l-methylephedrine hydrochloride, ephedrine

hydrochloride, phenylephedrine hydrochloride, pseudoephedrine hydrochloride,

phenylpropanolamine and a mixture thereof.

2

AMENDMENT UNDER 37 C.F.R. § 1.116

Application No.: 10/534,066

Attorney Docket No.: Q87744

3. (Original) The method of claim 1, wherein the co-surfactant is an organic solvent having a boiling point lower than 100 °C.

- 4. (Original) The method of claim 3, wherein the co-surfactant is ethanol.
- 5. (Original) The method of claim 1, wherein the surfactant is selected from the group consisting of polyoxyethylene hydrogenated vegetable oils, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene-sorbitan-fatty acid esters, polyoxyethylene fatty acid esters, sodium dioctyl sulfosuccinate or sodium lauryl sulfate, phospholipids, transestelification products of natural vegetable oil triglycerides and polyalkylene polyols, mono/diglycerides, sorbitan fatty acid esters and a mixture thereof.
- 6. (Original) The method of claim 1, wherein the oil is selected from the group consisting of esters of fatty acids and monovalent alkanols, propyleneglycol mono- or di-fatty acid esters, fatty acid triglycerides, mono/di-glycerides, natural vegetable or animal oils, carbohydrates, tocopherols and a mixture thereof.
- 7. (Original) The method of claim 1, wherein the water-insoluble anti-cold drug: co-surfactant: surfactant: oil ratio by weight is in the range of  $1:0.5\sim20:0.5\sim10:0.04\sim1$ .

AMENDMENT UNDER 37 C.F.R. § 1.116

Application No.: 10/534,066

Attorney Docket No.: Q87744

8. (Original) The method of claim 1, wherein the co-surfactant is removed in step (C) by heating the pre-concentrate at a temperature ranging from 50 to 100 °C.

9. (Currently amended) A microemulsion concentrate prepared by the method of claim 1 comprising a water-insoluble anti-cold drug, a surfactant and an oil, thereby forming microparticles having an average particle size ranging from 270 to 500 nm upon contact with an aqueous solution.

10. (Original) The microemulsion concentrate of claim 9, wherein the water-insoluble anti-cold drug: surfactant: oil ratio by weight is in the range of 1: 0.5~10: 0.04~1.

11. (Canceled)